Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
基本信息
- 批准号:10707830
- 负责人:
- 金额:$ 91.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAdoptedAdverse eventAgeAnimal ModelAnimalsApicalAreaBenchmarkingBiological AssayBiological ModelsBody mass indexCell Differentiation processCell SurvivalCell modelCell physiologyCellsCellular StructuresCessation of lifeClinicalClinical DataClinical TrialsColonCompetenceComplementCulture MediaDataData AnalysesData SetDevelopmentDiarrheaDiseaseDoseDose LimitingDrug EvaluationDrug ExposureDrug KineticsDrug ScreeningDrug TargetingEngineeringEpitheliumExcisionExposure toFee-for-Service PlansFeedbackFemaleGastrointestinal tract structureGoalsHumanImageImpairmentIn VitroIndustryInflammationIntestinesLife Cycle StagesManufacturerMarketingMeasuresMicroinjectionsModelingOncologyOrganoidsOutcomePharmaceutical PreparationsPharmacologic SubstancePhasePhysiologyPlasmaPopulationProliferatingPropertyProtocols documentationPublishingRattusRho-associated kinaseRiskRunningSafetySmall IntestinesSourceTechnologyTestingTherapeuticTherapeutic EffectTissue DonorsTissuesToxic effectToxicologyTransformed Cell LineTransverse colonTumor Cell LineTumor-DerivedUlcerValidationWorkadverse event riskcell typeclinical translationclinically relevantcommercial launchcost effectivedemographicsdetection assaydrug mechanismethnic diversityexperimental studygastrointestinalgastrointestinal epitheliumgastrointestinal systemimprovedin vitro Modelin vivointerestintestinal barrierintestinal epitheliumjejunumkinase inhibitorlead optimizationmalemetermonolayernovelnovel therapeuticsphase 1 studyphase 2 studyphase III trialpreclinical safetypreclinical studyregenerative cellrepairedresearch clinical testingrisk mitigationscreeningscreening servicesself-renewalside effectstemstem cell populationstem cell proliferationstem cellssuccesstherapeutic candidatetimeline
项目摘要
Project Summary
GI side effects, such as ulcers and diarrhea, represent the most common source of adverse events for
pharmaceuticals. GI stem cells are responsible for repairing and replenishing GI epithelium, and pharmaceutical
inhibition of these functions likely contribute to adverse event risk. Currently there are no high-throughput and
cost-effective means of screening candidate therapeutics for effects on GI stem cells. Animal models are fraught
with confounds (e.g., rats generally do not exhibit diarrhea until death is imminent) and current in vitro models
like the Caco-2 tumor cell line do not include a normal stem cell population. While 3D-organoid cultures have a
stem cell component, access to the apical aspect of the monolayer for compound exposure is not possible
without low-throughput microinjection. Altis Biosystems, Inc. has developed a proprietary culture platform,
RepliGut® Planar, enabling primary human GI cells to form an epithelium for drug screening. In preliminary
efforts, we initiated development of a GI stem cell-specific platform called RepliGut® StemScreen to address the
unmet need for high-throughput, cost-effective GI stem cell screening, including a range of assays to measure
properties that might lead to adverse events. These included assays related to stem cell proliferation, self-
renewal, and differentiation competency.
In our Phase 1 studies, we developed a 5 day, 96-well, plate-based screening assay (termed StemTox)
and tested a panel of pharmaceutical agents known to trigger GI side effects. The results revealed a highly
sensitive and dose-dependent inhibition of stem cell proliferation and impairment of intestinal barrier formation.
Furthermore, our assay detected “adverse” concentrations for compounds that closely paralleled the clinical
plasma Cmax associated with human clinical outcomes. In this Phase 2 application, we propose to complete
optimization of the StemTox screen, generate a commercial validation data set (using multiple tissue donors and
cell lots of transverse colon), and expand the model to integrate cell differentiation and long-term drug exposures.
Collectively, this work will result in the commercial launch of the StemTox assay, as well as, enable several
follow-on experimental paradigms to more comprehensively assess off-target drug mechanisms and repeat-
dosing experiments (to parallel current IND-enabling nonclinical study requirements).
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bill Thelin其他文献
Bill Thelin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bill Thelin', 18)}}的其他基金
MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes.
MetabolGut:一个快速检测平台,使用干细胞驱动的人体吸收性肠上皮细胞来评估药物对脂质处理途径和乳糜微粒相关药物分布的影响。
- 批准号:
10766493 - 财政年份:2023
- 资助金额:
$ 91.37万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 91.37万 - 项目类别:
Research Grant